Bryan, Garnier & Co Initiates Coverage on Cellectis (NASDAQ:CLLS)

Equities researchers at Bryan, Garnier & Co started coverage on shares of Cellectis (NASDAQ:CLLS – Get Rating) in a research note issued to investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. Bryan, Garnier & Co’s price target would indicate a potential upside of 219.15% from the stock’s previous close.

Several other brokerages also recently commented on CLLS. Oppenheimer dropped their target price on shares of Cellectis from $16.00 to $13.00 and set an “outperform” rating on the stock in a report on Monday, March 13th. Citigroup reduced their price target on shares of Cellectis from $36.00 to $24.00 in a research report on Wednesday, December 14th. StockNews.com assumed coverage on shares of Cellectis in a research report on Thursday. They set a “hold” rating on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $6.00 price objective on shares of Cellectis in a report on Monday, March 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.71.

Cellectis Price Performance

NASDAQ CLLS opened at $1.88 on Friday. The firm’s 50 day moving average price is $2.63 and its two-hundred day moving average price is $2.52. Cellectis has a twelve month low of $1.80 and a twelve month high of $5.04. The company has a current ratio of 2.28, a quick ratio of 2.65 and a debt-to-equity ratio of 0.16.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its position in shares of Cellectis by 11.0% during the 2nd quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock valued at $3,816,000 after acquiring an additional 133,587 shares during the period. Millennium Management LLC lifted its holdings in Cellectis by 18.5% during the fourth quarter. Millennium Management LLC now owns 679,966 shares of the biotechnology company’s stock valued at $1,428,000 after purchasing an additional 106,125 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Cellectis by 166.5% in the first quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after buying an additional 376,862 shares in the last quarter. State Street Corp increased its position in shares of Cellectis by 3.4% in the third quarter. State Street Corp now owns 262,368 shares of the biotechnology company’s stock worth $601,000 after purchasing an additional 8,643 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Cellectis by 21.6% in the third quarter. Oppenheimer & Co. Inc. now owns 91,963 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 16,330 shares during the last quarter. 22.61% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

(Get Rating)

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt’s proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals.